Saab, Sammy <br/><br/>
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.  [electronic resource] 

 -  Journal of medical economics  Aug 2016 
 - 795-805 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2016.1176030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anilides--economics<br/>Antiviral Agents--administration & dosage<br/>Benzimidazoles--economics<br/>Carbamates--economics<br/>Carcinoma, Hepatocellular--economics<br/>Cost-Benefit Analysis<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Fibrosis--economics<br/>Fluorenes--economics<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Neoplasms--economics<br/>Macrocyclic Compounds--economics<br/>Male<br/>Markov Chains<br/>Middle Aged<br/>Models, Econometric<br/>Proline--analogs & derivatives<br/>Quality-Adjusted Life Years<br/>Ribavirin--economics<br/>Simeprevir<br/>Sofosbuvir--economics<br/>Sulfonamides--economics<br/>Uracil--analogs & derivatives<br/>Valine